The Patented Medicine Prices Review Board (PMPRB) invites stakeholders to comment on two proposed consequential amendments to the new PMPRB Guidelines resulting from the decision to delay the coming-into-force date of the Regulations Amending the Patented Medicines Regulations (“Regulations”) a further six months, from January 1, 2021 to July 1, 2021. The PMPRB proposes to change the definition of Gap medicines and the timeline for compliance with the Maximum List Price (MLP) ceiling for Grandfathered and Gap medicines.
The deadline to submit written comments is February 15, 2021. Only feedback submitted to the PMPRB Consultations inbox will be accepted for consideration.
All future announcements of this type will be communicated through the PMPRB Twitter account. Please follow us to stay up to date on the latest PMPRB news.
PMPRB Consultation Team